Technology
Intellectual Property
The Company is the exclusive licensee of a portfolio of patents based on the work of Dr. Yvonne Paterson whose research at the University of Pennsylvania has resulted in a substantial base of intellectual property protecting the use of Listeria and listerial products as vaccine vehicles, in the form of several broad patents and applications that were filed both in the US and internationally. This includes 11 issued and over 35 pending U.S. patents. These patents are filed in the US as well as in Japan, Canada, Australia and Europe. In addition, the Company has a 3-year option to license from Penn any new invention conceived by either Dr. Yvonne Paterson or by Dr. Fred Frankel (a researcher at Penn and an inventor of one of the patents licensed to the Company) in the vaccine area. The Company will continue to expand its intellectual property base in the immunotherapeutic and vaccine area by exercising its option as well as by continuing to conduct research and development in its own labs and subsequently the filings of new Company owned patents.
The Company's approach for its intellectual property estate is to aggressively create significant offensive and defensive patent protection for every product and technology platform that it develops. Advaxis works closely with its patent counsel to maintain a coherent and aggressive strategic approach to building the Advaxis patent portfolio with an emphasis in the field of cancer vaccines.
Home Back to Top